Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF
Status:
Active, not recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The proposed study is an open-label, single-arm, Phase-Ib/II trial to assess the efficacy of
oral drug combination ruxolitinib and pomalidomide in primary and secondary MF patients.